KLB and intrahepatic cholangiocarcinoma: FGF19 is found to be low in most cancers; FGFR4 is highly expressed in many cancers, particularly in HCC and Intrahepatic Cholangiocarcinoma (ICC), with a significant difference in expression when compared to matched normal tissues; and KLB is found to be highly expressed in HCC patients’ cancer tissues and normal tissues adjacent to ICC patients.